“Brentuximab Vedotin (Antibody-drug conjugate, ADC)was approved by the FDA in 2011 as the first new therapeutic option for patients with Hodgkin lymphoma in more than 30 years. Currently, brentuximab vedotin and nivolumabRead More…
On August 24th, a reporter was informed from Prof. Guangmei Yan research group at Zhongshan University that this group of researchers identified and gained oncolytic virus M1 synergist with accurate treatment ofRead More…
Generally, when the business of a pharmaceutical giant reaches a plateau, its business volume won’t change much during this period. Instead, it will try to optimize its structure, including R&D and productionRead More…
In this month, FDA oncologic Drugs Advisory Committee agreed to the approval of Novartis’s CAR-T CTL019 therapy on a vote of 10:0 for the treatment of relapsed or refractory children and youngRead More…
Immunotherapy has become a new hope against cancer. CAR-T cell therapy is achieved by using genetic engineering method to express chimeric antigen receptors on T cells obtained from donner patients. These chimericRead More…
Novartis’ chimeric antigen receptor T cell therapy (CAR-T) was supported and approved unanimously (10-0) on July 12th by the U.S. FDA Advisory Committee experts. This vote marks the key milepost of thisRead More…
On July 12, FDA experts will discuss whether CAR-T CTL019 can be on the market, which is an assessment of the CTL019 Biologics License Application (BLA) submitted by Novartis and will evaluateRead More…
According to the Journal of the American Medical Association, there were 15.4 million cancer patients worldwide in 2013. Among them, the cancer mortality rate in developing countries was higher than that ofRead More…
Let’s see the other five Top 10 Best Selling drugs ranking from 6th to 10th. 6. Trastuzumab Trastuzumab (trade name: Herceptin) is a humanized monoclonal antibody. It targets HER2, blocks the functionRead More…
With Trump’s coming into power and the economic upheavals of Europe, the new drug approved by the FDA fell to a record low in 2016, following which the drug market of 2017Read More…